Skip to main navigation
For Patients
|
For Physicians
logo

Header Links

  • Solutions
  • Investors
    • Overview
    • Stock Information
    • News & Events
    • Financial Information
    • Corporate Governance
    • Investor Resources
  • Meet the Team
  • News
  • Careers
  • Contact Us
  • For Patients
  • For Physicians

Quarterly Earnings

Financial Information

  • SEC Filings
  • Annual Reports
  • Quarterly Results
  • Presentations

Bundled Content

Show all

2022

Q1
  • Earnings Release
  • Form 10-Q

2021

Q4
  • Earnings Release
  • Form 10-K
Q3
  • Earnings Release
  • Form 10-Q
Q2
  • Earnings Release
  • Form 10-Q
Q1
  • Earnings Release
  • Form 10-Q

2020

Q4
  • Earnings Release
  • Form 10-K
Q3
  • Earnings Release
  • Form 10-Q
Q2
  • Earnings Release
  • Form 10-Q
Q1
  • Earnings Release
  • Form 10-Q

2019

Q4
  • Earnings Release
  • Form 10-K
Q3
  • Earnings Release
  • Form 10-Q
Q1
  • Earnings Release
  • Form 10-Q

2018

Q4
  • Earnings Release
  • Form 10-K
Q3
  • Earnings Release
  • Form 10-Q
Q2
  • Earnings Release
  • Form 10-Q

Shareholder Tools

  • View printer-friendly version
  • RSS Feeds
  • E-mail Alerts
  • View contacts
Indication

NeuroStar TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

NeuroStar TMS Therapy is only available by prescription. A doctor can help decide if NeuroStar TMS Therapy is right for you.

Important Safety Information

The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of NeuroStar TMS (<0.1% per patient).

TMS Therapy should not be used with patients who have non-removable conductive metal in or near the head. NeuroStar TMS Therapy has not been studied in patients who have not received prior antidepressant
Safety and Prescribing Information »

Our Commitment

Neuronetics is committed to compliance with state and federal laws regarding interaction with healthcare providers.
Commitment to Compliance »

Copyright @ 2022 Neuronetics Inc. All Rights Reserved.

Social Links

  • facebook
  • instagram
  • youtube
  • linkedin
  • twitter

To find out more about NeuroStar TMS Therapy® or where treatment is available near you, please provide your contact information and a Neuronetics customer service representative will contact you. The information you provide to us is subject to the Neuronetics Privacy Policy.

General Contact Information

Customer Service Center: 1-877-600-7555